11 May 2009: NorDiag has entered into a cooperation agreement with Kitron regarding preparation of NorDiag's  "Arrow" instrument for batch production. It is the parties' intention to firm up and sign an agreement concerning batch production of "Arrow" within August 2009.

CEO in NorDiag, Mårten Wigstøl comments:  "In accordance with plan, we launched "Arrow" in March this year and the market response so far is unconditionally positive. The "Arrow" instrument is suitable for DNA diagnostics for small to medium size laboratories and it is affordable, closed and "true walk away" system. The instrument is designed to handle difficult samples such as urine, sputum and stool. The volume potential is huge, and the use of it can be expanded beyond DNA based diagnostics.  We have thus emphasized attaching a reliable producer with medical and reproduceable batch production experience, which can provide us with the volume flexibility needed to meet expected demand and high growth".

Managing Director in Kitron, Dag Songedal, is happy with cooperating with NorDiag: "The agreement will allow us to use our competence within volume production of medical equipment and NorDiag as a customer suits us very well".

Kitron expects NorDiag to be a significant customer in the future.

Kitron has experience from batch production, including such production of medical equipment. Both NorDiag and Kitron are certified according to ISO 9001:2000 and ISO 13485.

Contact:
CEO Mårten Wigstøl, phone +47 911 65775

About NorDiag:
NorDiag is a biotechnology company developing, manufacturing and marketing automated solutions, instruments and tests, for use in diagnostic of infectious diseases and cancer. The Company`s core competence is isolation of bacterial and human DNA from difficult clinical samples, and the Company has established a solid market share in the Scandinavian market for sexually transmitted infections. The company has similar applications for Tuberculosis, MRSA and DNA from stool. Applications for respiratory pathogens and viruses are under development. NorDiag was founded in 2003 and has its headquarters in Oslo - Norway. The Company has offices and laboratories in Stockholm - Sweden and West Chester (PA) - USA. The group has 36 employees. NorDiag is listed on Oslo Stock Exchange with the ticker NORD. For further information - www.nordiag.com.

Read the notice in Norwegian here